Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis

Groenewegen, 2020, Epidemiology of heart failure, Eur J Heart Fail, 22, 1342, 10.1002/ejhf.1858 Murphy, 2020, Heart failure with reduced ejection fraction: a review, JAMA, 324, 488, 10.1001/jama.2020.10262 Tsao, 2018, Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction, JACC: heart failure, 6, 678 McDonagh, 2021, Eur Heart J, 42, 3599, 10.1093/eurheartj/ehab368 Jhund, 2016, The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan, Heart, 102, 1342, 10.1136/heartjnl-2014-306775 McMurray, 2014, Angiotensin–neprilysin inhibition versus enalapril in heart failure, N Engl J Med, 371, 993, 10.1056/NEJMoa1409077 Wachter, 2019, Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study, Eur J Heart Fail, 21, 998, 10.1002/ejhf.1498 McDonald, 2021, CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction, Can J Cardiol, 37, 531, 10.1016/j.cjca.2021.01.017 Maddox, 2021, J Am Coll Cardiol, 77, 772, 10.1016/j.jacc.2020.11.022 Sterne, 2016, ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions, BMJ, 355, i4919, 10.1136/bmj.i4919 De Vecchis, 2019, Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction: a retrospective cohort study, Herz, 44, 425, 10.1007/s00059-017-4671-1 Polito, 2020, Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction, Sci Rep, 10, 6665, 10.1038/s41598-020-63801-2 Tan, 2020, Comparative effectiveness of sacubitril-valsartan versus ACE/ARB therapy in heart failure with reduced ejection fraction, JACC Heart Fail, 8, 43, 10.1016/j.jchf.2019.08.003 Greene, 2021, Clinical effectiveness of sacubitril/valsartan among patients hospitalized for heart failure with reduced ejection fraction, J Am Heart Assoc, 10, 10.1161/JAHA.121.021459 Chen, 2021, Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: a multi-institution study, EClinicalMedicine., 41, 10.1016/j.eclinm.2021.101149 Rattanavipanon, 2021, Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis, BMC Cardiovasc Disord, 21, 324, 10.1186/s12872-021-02145-9 Martens, 2019, Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions, Acta Cardiol, 74, 115, 10.1080/00015385.2018.1473825 Antol, 2018, An early view of real-world patient response to sacubitril/valsartan: a retrospective study of patients with heart failure with reduced ejection fraction, Adv Ther, 35, 785, 10.1007/s12325-018-0710-4 Vicent, 2019, Sacubitril/valsartan in daily clinical practice: data from a prospective registry, J Cardiovasc Pharmacol, 73, 118, 10.1097/FJC.0000000000000641 Giovinazzo, 2021, Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis, ESC Heart Fail, 8, 3547, 10.1002/ehf2.13547